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Abstract
Background:  N-acetyltransferase 2 is phase II metabolizing enzyme that participates in the
bioconversion of heterocyclic arylamines into electrophilic nitrenium ions, which are important
ultimate carcinogens that are directly implicated in tumor initiation process. This study was
conducted to examine; (1) whether the N-acetyltransferase 2 (NAT2) genotype is a risk factor for
prostate cancer, (2) to study effect of NAT2 genotype on modifying prostate cancer risk from
tobacco use.
Methods: The case control study was undertaken over a period of 28 months and included 130
prostate cancer patients (CaP) and 140 controls. The NAT2 genotypes were identified by PCR-
RFLP method in DNA extracted from peripheral blood. Genotype frequencies and the association
of genotypes with patients and control groups were assessed by logistic regression model.
Results: We observed non-significant association of rapid acetylator genotype NAT2 (OR = 1.452,
95% CI: 0.54–1.87, P = 0.136) in prostate cancer patients. However significant association was
observed between rapid acetylator genotype NAT2 and CaP tobacco users (OR = 3.43, 95% CI:
1.68–7.02, P-value < 0.001) when compared with controls.
Conclusion: The data suggests that the NAT2 rapid acetylator genotypes may play an important
role in determining the risk of developing prostate cancer particularly in the tobacco users of north
Indian population.
Background
The human N-acetylation polymorphism is a genetic trait
phenotypically allied by variation in N-acetyltransferases
2 (NAT2) activity with therapeutic agents. Acetylation pol-
ymorphism arises from the allelic variations in human
arylamine N-acetyltransferases 2 resulting in the produc-
tion of NAT2 proteins with variable enzyme activity or sta-
bility. Certain drugs and chemicals may contribute to the
occurrence of adverse drug effects and act as susceptibility
factors for certain malignancies such as prostate and blad-
der cancer [1,2]. NAT2 is one of the phase II enzyme that
participate in the bioconversion of heterocyclic
arylamines into electrophilic nitrenium ions, which are
important ultimate carcinogens that are directly impli-
cated in tumor initiation process [3]. It is expressed at
high level in liver and encoded by a polymorphic gene
presenting several nucleotide substitutions. Consequently
the presence of the different alleles in each individual
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genome produce a broad range of metabolic phenotypes
that vary from fully active rapid metabolizers to the less
active alleles of slow metabolizers [4]. Many chemical and
dietary carcinogens, such as nitrosoamines and
arylamines derived from dietary fat as well as tobacco
users product, acquire bioactivation and inactivation by
enzymes. This suggests that polymorphism of genes
encoding metabolic enzymes may represent potential risk
factors [5-7].
Some studies indicated that genetically variable NATs,
CYP P450 and GSTs are involved in the metabolism of
drugs, carcinogens and natural products; and may be
responsible for cancer susceptibility [7,8]. It has been
reported that rapid acetylators genotypes of NAT2 may be
at increased risk of liver and colon cancer [9], hepatocel-
lular carcinoma [10] and colorectal cancer [11] when
exposed to environmental arylamines carcinogens, due to
NAT2 rapid acetylator mediated O-acetylation. Recent
molecular epidemiological studies have analyzed the rela-
tionship between various metabolic enzymes, such as N-
acetyltransferases (NATs) and cytochrome P450 (CYP) in
etiology of prostate cancer [12,13].
It is known that human express two forms of N-acetyl-
transferases: NAT1 and NAT2; both genes are polymor-
phic. A recent review reported the nucleotide and amino-
acid changes associated with various alleles and deduced
phenotype from genotype. It also summarized results of
molecular epidemiologic studies assessing the association
of NAT1 and NAT2 genotypes with cancer risk of bladder,
colon, breast, lung, head and neck and prostate [14]. A
review by Chen, (2001) in prostate cancer suggests that
the frequencies of some polymorphisms in certain genes
differ among different racial and ethnic groups [15].
Whether these genetic variants can help explain part of the
large differences in prostate cancer risk in various popula-
tions await further clarification.
The present study was undertaken to study the following
objectives, i) To observe the frequencies of rapid and slow
acetylators (NAT2) in CaP and control individuals ii) to
study effect of NAT2 genotype on modifying prostate can-
cer risk from tobacco use.
Methods
Patient selection
The study group consisted of 130 prostate cancer patients
mean age (63.3 ± 9.9) and 140 normal healthy controls
mean age (56.7 ± 13.9). The criteria for the patient selec-
tion was based on clinical proforma, pathological, and
histo-pathological records from the outpatient depart-
ment of Sanjay Gandhi postgraduate institute of medical
science, Lucknow. This study was approved by ethical
committee of the Institute. Only histologically confirmed
prostate cancer patients were included in the study. All
cancer patients had higher Gleason scores (6–9) and was
detected at advance stage due to lack of structured screen-
ing program under any health scheme in our country.
Informed consent was obtained from each participant.
The inclusion criteria for the controls were absence of any
prior history of cancer or pre-cancerous lesions. Serologi-
cal (prostate serum antigen, < 4 ng/dl), physical (digital
rectal examination) and radiological examinations were
performed in all control individuals in order to exclude
the possibility of malignancy. The consumption of
tobacco in any form (cigarette/ bidi smoking, chewing
tobacco in beetle leaf, pan-masala/ gutka etc.) in both
groups (cases and controls) was noted through a detailed
questionnaire. The criteria of non-users are persons who
never use tobacco related material like cigarette/ bidi
smoking, pan-masala/ gutka, or chewing tobacco in beetle
leaf whereas tobacco user were those who used all these
carcinogenic material. These questionnaires were pub-
lished in our other studies [24-26].
PCR-RFLP and alleles genotyping
Genomic DNA was isolated from peripheral leucocytes by
Proteinase -K digestion and phenol/chloroform method
[16]. The NAT2 genotypes were determined using the
PCR-RFLP as described previously [17]. PCR product of
1093 bp was generated by polymerase chain reaction
using the following primer:
Forward 5'-TCTAGCATGAATCACTCTGC-3'
Reverse 5'- GGAACA AATTGG AC TTGG -3'.
Genomic DNA 200 ng was added to a PCR mixture, com-
prising 18.5 pmol of each primer, 200 µmol dNTP, 1.5
unit of Taq polymerase, and 5 µl, 10X PCR buffer (10
mmol/ml Tris HCl pH = 8.4, 50 mmol/ml KCl and 2.5
mol/ml MgCl2) in a total volume of 50 µl. PTC-100 ther-
mocycler (MJ Research, U.S.A.) for polymerase chain reac-
tion was employed. The reaction mixture was subjected to
initial denaturation at 94°C for 5 min, followed by 35
cycles (94°C, 1 min), annealing (58.5°C, 1 min) and
extension (72°C, 1 min). The final extension was done at
72°C for 10 min. Following PCR, 7 µl of PCR products
were digested with four separate enzymes including Kpn1
for NAT2*5 allele, at 37°C for 2 hrs; Taq1 for NAT2*6
allele, at 56°C for 4 hrs; BamH1 for NAT2*7 allele at
37°C for 2 hrs; and Alu1 for NAT2*14 allele at 37°C for
2 hrs. Digested product was run on 2% agarose gel for
NAT2*5, NAT2*7, NAT2*14 alleles and 3% agarose gels
for NAT2*6 allele.
NAT2 have many alleles but more common alleles stud-
ied frequently are NAT2*5, NAT2*7, NAT2*14 and
NAT2*6 allele as described in the present study also.BMC Urology 2005, 5:12 http://www.biomedcentral.com/1471-2490/5/12
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However, we could not genotypes many other additional
alleles of NAT2, which could be the limitation in our
study.
Estimating the frequency of rapid and slow acetylator
The variant and non-variant NAT2 alleles were recorded
and rapid or slow acetylator phenotype assignments were
deduced on the basis of NAT2 genotype [4]. Genotypes
possessing two variant alleles (NAT2*5, NAT2*6,
NAT2*7, or NAT2*14) were assigned as slow acetylator
phenotype whereas others were assigned as rapid acetyla-
tor phenotype.
Statistical analysis
Statistical analysis was done with SPSS 11.5 software pro-
gram. Differences in genotype prevalence and association
between case and control groups were assessed by binary
logistic regression model. Odds ratios (OR) and its 95%
confidence interval (CI) were obtained by summarizing
data over two habit strata (tobacco users/ non-users). We
evaluated age adjusted (confounder OR) and age unad-
justed odds ratios, and 95% CI using logistic regression
models. Univariant analysis, odds ratios, and 95% CI
were used to describe the strength of association.
Results
Comparative details of the observed frequency of different
alleles are presented in (Table 1); which indicates signifi-
cant interethnic variation in NAT2 genotypes in different
populations. The NAT2*5 and NAT2*6 allele is most
commonly present in our population and also in South
Indian and Caucasian- American population but is rare in
Japanese population, whereas the NAT2*14 allele is only
found in African – American population.
The distribution of genotypes of NAT2 in control and can-
cer patients is shown in (Table 2). Higher frequency of
NAT2 rapid acetylator was observed (64.6%) among the
patient groups as compared to the controls (55.7%).
However, this was statistically non significant (OR =
1.452, 95% CI: 0.54–1.87, P = 0.136).
The association between tobacco users and NAT2 geno-
types are summarized in (Table 3). The OR for the rapid
acetylator genotypes verses slow acetylator genotypes was
3.43 fold higher for the susceptibility of prostate cancer as
compared to the controls (OR = 3.43, 95% CI: 1.68–7.02,
P-value = 0.001) (Table 3).
We categorized prostate serum antigen value (PSA) into
three group (PSA = <10 ng/ml, >10 ng/ml,>20 ng/ml) and
Gleason score into two group (GS = 6–7 and 8–9). And we
observed that NAT2 genotypes were non-significant with
PSA (P = 0.090) or Gleason score (= 0.678) for risk of
prostate cancer in our population (Fig 1 and Fig 2).
Discussion
The present NAT2 genotyping study based on molecular
methods in discriminating the acetylator genotypes both
in controls and prostate cancer patients is the first of its
kind in north Indian population. Rapid acetylator geno-
types were comparatively predominant (55.7% and
Table 1: Frequency of NAT2 alleles in of north Indian control and other ethnic population.
Population Allelic frequency of NAT2 Reference
NAT2*5 NAT2*6 NAT2*7 NAT2*14
North Indians (n = 140) 0.50 0.30 0. 25 0.0 Present study
South Indians (n = 166) 0. 22 0.37 0. 25 0.0 [20]
Caucasian-American (n = 372) 0. 45 0.28 0.02 0.0 [22]
African – American (n = 128) 0.30 0. 22 0.02 0.09 [22]
Japanese (n = 173) 0.01 0.20 0.13 – [1]
Table 2: Frequency distribution of NAT2 genotypes in prostate cancer patients and controls.
Patients NAT2 genotype P – value Unadjusted OR (95% CI) Adjusted OR
Slow – acetylators Rapid-acetylators
Controls (n = 140) 62 (44.29%) 78 (55.71%) 1.0 (Reference) 1.0
Prostate cancer (n = 130) 46 (35.38%) 84 (64.62%) 0.136 1.452 (0.54–1.87) 1.348 (0.39–2.28)
Adjusted OR = Age adjusted odds ratio.BMC Urology 2005, 5:12 http://www.biomedcentral.com/1471-2490/5/12
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64.6%) as compared to the slow acetylator genotypes
(44.3% and 35.4%).
The results observed in the present study suggest, that
NAT2 genotype has a trend of association for prostate
cancer risk when considered alone (OR = 1.452, 95% CI:
0.54–1.87, P = 0.136) but is statistically non-significant
(Table 2). However, no association could be established
between NAT2 genotype and PSA and/or Gleason score
(Fig 1 and Fig 2). Our findings agree with previous studies
that showed significant association of prostate cancer for
NAT2 rapid acetylator genotype in American study (23)
whereas non significant association was observed in
Swedish, Danish [12]) and Spanish population [13]. On
the contrary, there was significant association reported
with slow acetylator genotypes of NAT2 in Japanese
population [1]. The discrimination in association study
from our observation could be related to ethnic variation.
However, in the present study we observed significant
association between the NAT2 genotypes in tobacco users
as compared to the controls (Table 3). The synergistic
interaction between the rapid acetylators genotype with
tobacco users obtained in our study implies that exposure
to tobacco, activates heterocyclic amines that are sub-
strates for NAT2 which may increase the risk for prostate
cancer. These observations are in agreement with the
reports published by the investigators in liver and colon.
In the liver heterocyclic amines may be N-hydroxylated by
the hepatic CYP1A2, and in turn O-acetylated by NAT
enzymes to an active form that can develop DNA adducts
[5,9]. NAT2 genotypes studied in hepatocellular carci-
noma [10] and colorectal cancer [11] have indicated the
Table 3: Association between NAT2 acetylator genotypes with tobacco users and prostate cancer patients.
Tobacco users / non -
users
Controls (n = 140) Ca-Prostate (n = 130) P-value Unadjusted OR (95% 
CI)
Adjusted OR (95% CI)
Non-users
Slow – acetylator 43(42.16) 29 (42.03) 1.0(Ref) 1.0(Ref)
Rapid-acetylator 59(57.84) 40(57.97) 0.987 1.01(0.49–2.11) 1.04(0.54–2.03)
Tobacco Users
Slow – acetylator 19 (50%) 17(27.87) 0.492 1.33(0.49–2.47) 1.45 (0.61–3.46)
Rapid-acetylator 19 (50%) 44(72.13) 0.001 3.43(1.68–7.02) 4.37(2.02–9.45)
Adjusted OR = Age adjusted odds ratio.
<10 = PSA (prostate serum antigen) value less than 10 ng/ml,  >10 = PSA value in between 10–20 ng/ml and >20 = PSA  value greater than 20 ng/ml Figure 1
<10 = PSA (prostate serum antigen) value less than 10 ng/ml, 
>10 = PSA value in between 10–20 ng/ml and >20 = PSA 
value greater than 20 ng/ml.
6–7 = Gleason score 6 and 7, 8–9 = Gleason score 8 and 9 of  prostate tumor Figure 2
6–7 = Gleason score 6 and 7, 8–9 = Gleason score 8 and 9 of 
prostate tumor.BMC Urology 2005, 5:12 http://www.biomedcentral.com/1471-2490/5/12
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prevalence of rapid acetylator among patient population.
Thus, the present study suggests that rapid acetylator gen-
otype could be associated with the susceptibility to pros-
tate cancer especially in tobacco users. The mechanisms
behind this association indicate that the slow acetylator
genotypes should decrease the generation of critical intra-
cellular concentration of such ultimate carcinogens, and
thus reduce tumorogenesis upon environmental exposure
(tobacco users). However, rapid acetylator genotypes
should increase the generation of such ultimate carcino-
gens and enhance tumorogenesis by the pathway of O-
acetylation. The results found in the present study reveal a
markedly increased frequency of allele encoding the active
genotype, among the patients cohort that entirely fit the
above model, and are consistent with genotype / pheno-
type based studied that demonstrate an excess of rapid
acetylator among the prostate cancer patients.
In the controls, slow allele of NAT2 is present up to 90%
in Arab population [21], 40–60% in Caucasians including
Indian [18] and 5–25% East Asian [19]. We observed 44%
of slow acetylator genotypes; however, another study
from South Indian population indicated 74% of slow
acetylator genotype [20]. Thus it indicates that frequency
of slow allele observed in our population matched with
studies in Caucasians population [18]. Differences of dis-
tribution of slow allele of NAT2 between our and south
Indian population is due to the different ethnic /or geo-
graphical environment.
Conclusion
In conclusion, this study indicates that NAT2 rapid
acetylator genotype exhibit a trend of association with the
risk of developing prostate cancer, and more so in case of
patients who are tobacco users.
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